PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

Janis M. Taube, Alison Klein, Julie R. Brahmer et al. · Clinical Cancer Research · 2014 · 2.3K citations · Full text

Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma

John Bridgewater, Peter R. Galle, Shahid A. Khan et al. · Journal of Hepatology · 2014 · 1.5K citations

Programmed death ligand-1 expression in non-small cell lung cancer

Vamsidhar Velcheti, Kurt A. Schalper, Daniel Carvajal et al. · Laboratory Investigation · 2013 · 750 citations · Full text

Tumor Biology, Medicine, Cell Death +6

Clinical impact of programmed cell death ligand 1 expression in colorectal cancer

Raoul A. Droeser, Christian Hirt, Carsten T. Viehl et al. · European Journal of Cancer · 2013 · 445 citations

Tumor Biology, Medicine, Apoptosis +9

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial

David Malka, Pascale Cervera, Stéphanie Foulon et al. · The Lancet Oncology · 2014 · 409 citations · Full text

Advanced Biliary-tract Cancer, Gastrointestinal Oncology, Medicine +7